Cholangiocarcinoma.
Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M.
Pathologica. 2021 Jun;113(3):158-169. doi: 10.32074/1591-951X-252.
Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract.
Norton JA, Foster DS, Blumgart LH, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT.
JAMA Surg. 2018 Mar 1;153(3):e175083. doi: 10.1001/jamasurg.2017.5083.
Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors.
Adsay NV, Basturk O, Saka B, Bagci P, Ozdemir D, Balci S, Sarmiento JM, Kooby DA, Staley C, Maithel SK, Everett R, Cheng JD, Thirabanjasak D, Weaver DW.
Am J Surg Pathol. 2014 Apr;38(4):480-93. doi: 10.1097/PAS.0000000000000165.
Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma.
Lu H, Liang B, Xia X, Zheng C.
BMC Cancer. 2024 Sep 2;24(1):1085. doi: 10.1186/s12885-024-12864-9.
Targeting cholangiocarcinoma.
Mertens JC, Ilyas SI, Gores GJ.
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24.
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A.
J Hepatol. 2023 Mar;78(3):614-626. doi: 10.1016/j.jhep.2022.11.030. Epub 2022 Dec 15.
Intrahepatic cholangiocarcinoma.
Nakano M, Ariizumi SI, Yamamoto M.
Semin Diagn Pathol. 2017 Mar;34(2):160-166. doi: 10.1053/j.semdp.2016.12.012. Epub 2017 Jan 5.
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Roth GS, Verlingue L, Sarabi M, Blanc JF, Boleslawski E, Boudjema K, Bretagne-Bignon AL, Camus-Duboc M, Coriat R, Créhange G, De Baere T, de la Fouchardière C, Dromain C, Edeline J, Gelli M, Guiu B, Horn S, Laurent-Croise V, Lepage C, Lièvre A, Lopez A, Manfredi S, Meilleroux J, Neuzillet C, Paradis V, Prat F, Ronot M, Rosmorduc O, Cunha AS, Soubrane O, Turpin A, Louvet C, Bouché O, Malka D.
Eur J Cancer. 2024 May;202:114000. doi: 10.1016/j.ejca.2024.114000. Epub 2024 Mar 13.
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.
Schönherr H, Ayaz P, Taylor AM, Casaletto JB, Touré BB, Moustakas DT, Hudson BM, Valverde R, Zhao S, O'Hearn PJ, Foster L, Sharon DA, Garfinkle S, Giordanetto F, Lescarbeau A, Kurukulasuriya R, Gerami-Moayed N, Maglic D, Bruderek K, Naik G, Gunaydin H, Mader MM, Boezio AA, McLean TH, Chen R, Wang Y, Shaw DE, Watters J, Bergstrom DA.
Proc Natl Acad Sci U S A. 2024 Feb 6;121(6):e2317756121. doi: 10.1073/pnas.2317756121. Epub 2024 Feb 1.
Schwannoma of Common Bile Duct: A Clinico-Radiologic Diagnostic Quagmire - A Case Report.
Thakur S, Dash NR, Barwad A, Das P, Madhusudhan KS, Yadav R.
GE Port J Gastroenterol. 2023 Oct 25;31(4):1-8. doi: 10.1159/000534300. Online ahead of print.
